Skip to main content
OpenTrials
Completed

NCT Number: NCT04841902

Effects of Life Style Intervention Manual in Pre Hypertensive Sedentary Population

Hypertension is an increasingly important medical and public health issue. The prevalence of hypertension increases with advancing age to the point where more than half of people 60-69 years of age and approximately three-fourths of those 70 years of age and older are affected. The age related rise in SBP is primarily responsible for an increase in both incidence and prevalence of hypertension with increasing age. At present, it is estimated that about 1 billion people worldwide have hypertension (>140/90 mmHg), and this number is expected to increase to 1.56 billion by 2025.

Because of the new data on lifetime risk of hypertension and the impressive increase in the risk of cardiovascular complications associated with levels of BP previously considered to be normal, the JNC 7 report has introduced a new classification that includes the term "prehypertension" for those with BPs ranging from 120-139 mmHg systolic and/or 80-89 mmHg diastolic. This new designation is intended to identify those individuals in whom early intervention by adoption of healthy lifestyles could reduce BP, decrease the rate of progression of BP to hypertensive levels with age, or prevent hypertension entirely. Prehypertension is not a disease category. Rather, it is a designation chosen to identify individuals at high risk of developing hypertension, so that both patients and clinicians are alerted to this risk and encouraged to intervene and prevent or delay the disease from developing. Individuals who are pre hypertensive are not candidates for drug therapy based on their level of BP and should be firmly and unambiguously advised to practice lifestyle modification in order to reduce their risk of developing hypertension in the future.

The goal for individuals with prehypertension and no compelling indications is to lower BP to normal levels with lifestyle changes, and prevent the progressive rise in BP using the recommended lifestyle modifications.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pre Hypertension Cardiovascular Diseases Prehypertension Vascular Diseases

Age range

25 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Riphah Rehabiliation Clinic

Lahore, Punjab Province, 54770, Pakistan

About this study

Adoption of healthy lifestyles by all persons is critical for the prevention of high BP and is an indispensable part of the management of those with hypertension. Weight loss of as little as 10 lbs (4.5 kg) reduces BP and/or prevents hypertension in a large proportion of overweight persons, although the ideal is to maintain normal body weight. BP is also benefited by adoption of the Dietary approaches to Stop Hypertension (DASH) eating plan which is a diet rich in fruits, vegetables, and low fat dairy products with a reduced content of dietary cholesterol as well as saturated and total fat (modification of whole diet). It is rich in potassium and calcium content. Dietary sodium should be reduced to no more than 100 mmol per day (2.4 g of sodium). Everyone who is able should engage in regular aerobic physical activity such as brisk walking at least 30 minutes per day most days of the week. Lifestyle modifications reduce BP, prevent or delay the incidence of hypertension, enhance antihypertensive drug efficacy and decrease cardiovascular risk. For example, in some individuals, a 1,600 mg sodium DASH eating plan has BP effects similar to single drug therapy. Combinations of two (or more) lifestyle modifications can achieve even better results. For overall cardiovascular risk reduction, patients should be strongly counseled to quit smoking.

Lifestyle modification involves altering long-term habits, typically of eating or physical activity, and maintaining the new behavior for months or years. Lifestyle changes are a more natural way toward therapeutic goals and should be an integral component of halting or even reversing early vascular aging as in pre hypertensive subjects. From a public health perspective, even a small reduction in BP should have a tremendous, beneficial effect on the occurrence of hypertension and its complications. In view of the current epidemic of BP-related diseases and the proven effects of lifestyle modifications on BP, the current challenge to health care providers, researchers, and public officials is to develop and implement effective life style intervention program comprising exercise dietary and educative component in clinical and public health strategies that achieve and maintain healthy lifestyle modification

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged between 25 - 40 years
  • Either gender
  • Clinic BP will be consistent with the diagnosis of pre-hypertension
  • Sedentary Subjects (<150 min/week or <600 MET-min/week on IPAQ Urdu Version)

Exclusion criteria

  • Body Mass Index less than 18.5 kg/m2 or greater than 45 kg/m2
  • Evidence of target organ damage such as left ventricular hypertrophy, angina, heart failure, stroke, chronic kidney disease, peripheral artery disease
  • Women of child-bearing age who tested positive for HCG & breastfeeding women
  • Individuals who could not read the consent or Participated in another study within 3 months

Treatment and study plan

Life Style Intervention Manual (With Exercise Under Supervision)

Other

Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. The exercise will be supervised will other two components will be home based.

General advice

Other

General advice to stay healthy and active

Life Style Intervention Manual (Home Based)

Other

Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. All three components will be home based.

Primary outcomes

  1. Change in Blood Pressure

    Time frame: 16 Weeks

    Office, Ambulatory, Daytime, Nighttime & 24 hours Systolic & Diastolic Blood Pressure, Mean Arterial Blood Pressure measured at baseline, 8th Week post treatment and 16th Week post treatment

  2. Change in Serum Triglycerides

    Time frame: 16 Weeks

    Serum Triglycerides measured at baseline, 8th Week post treatment and 16th Week post treatment

  3. Change in Body Mass Index (BMI)

    Time frame: 16 Weeks

    Body Mass Index (BMI) measured at baseline, 8th Week post treatment and 16th Week post treatment. BMI is calculated using height (m) and weight (kg) using the formula kg/m^2

  4. Change in Forced Vital Capacity (FVC)

    Time frame: 16 Weeks

    Forced Vital Capacity (FVC) measured at baseline, 8th Week post treatment and 16th Week post treatment using a digital spirometer.

  5. Change in Serum Total Cholesterol

    Time frame: 16 Weeks

    Serum Total Cholesterol measured at baseline, 8th Week post treatment and 16th Week post treatment from intravenous blood specimen.

  6. Change in Serum High Density Lipoprotein (HDL-C)

    Time frame: 16 Weeks

    Serum High Density Lipoprotein (HDL-C) measured at baseline, 8th Week post treatment and 16th Week post treatment from intravenous blood specimen.

  7. Change in Serum High Density Lipoprotein (LDL-C)

    Time frame: 16 Weeks

    Serum High Density Lipoprotein (LDL-C) measured at baseline, 8th Week post treatment and 16th Week post treatment from intravenous blood specimen.

  8. Change in Forced Expiratory Volume - 01 Second (FEV1)

    Time frame: 16 Weeks

    Forced Expiratory Volume - 01 Second (FEV1) measured at baseline, 8th Week post treatment and 16th Week post treatment using digital spirometer.

  9. Change in Forced Expiratory Volume 1 Second / Forced Vital Capacity (FEV1/FVC)

    Time frame: 16 Weeks

    Forced Expiratory Volume 1 Second / Forced Vital Capacity (FEV1/FVC) measured at baseline, 8th Week post treatment and 16th Week post treatment using digital spirometer.

  10. Change in Peak Expiratory Flow Rate (PEFR)

    Time frame: 16 Weeks

    Peak Expiratory Flow Rate (PEFR) measured at baseline, 8th Week post treatment and 16th Week post treatment using digital spirometer.

  11. Change in Body Fat Percentage

    Time frame: 16 Weeks

    Body Fat Percentage measured at baseline, 8th Week post treatment and 16th Week post treatment using a body fat analyzer

  12. Change in Waist-Hip Ratio

    Time frame: 16 Weeks

    Waist-Hip Ratio measured at baseline, 8th Week post treatment and 16th Week post treatment. Waist and hip circumference will be measured using inelastic tape.

  13. Change in Hand Grip Strength

    Time frame: 16 Weeks

    Hand Grip Strength (Dominant & Non Dominant)measured at baseline, 8th Week post treatment and 16th Week post treatment using Hand Held Dynamometer.

  14. Change in VO2 Maximum

    Time frame: 16 Weeks

    VO2 Maximum measured at baseline, 8th Week post treatment and 16th Week post treatment using treadmill.

  15. Change in Level of Perceived Exertion

    Time frame: 16 Weeks

    Level of Perceived Exertion measured at baseline, 8th Week post treatment and 16th Week post treatment using BROG scale.

Sponsors and collaborators

Lead sponsor

Riphah International University

Other

Registry information

Official study title

Effects of Life Style Intervention Manual on Metabolic, Cardiovascular, Respiratory and Physical Parameters in Pre Hypertensive Sedentary Population

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Apr 12, 2021
Registry last updated
Apr 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.